# US 11,268,070 B2 · Methods for creating integration-free, virus-free, exogenous oncogene-free IPS cells and compositions for use in such methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,268,070 B2
- Document ID: US11268070B2
- Status: Granted
- Kind: B2
- Application number: 15/954,291
- Filed: 2018-04-16
- Published: 2019-10-17
- Granted: 2022-03-08
- Earliest claimed: 2018-04-16
- Assignees: Cellular Engineering Technologies, Inc.
- Applicants: Cellular Engineering Technologies, Inc.
- Inventors: Alan B. Moy; Anant Kamath
- Web page: https://patentgrep.com/patent/US11268070B2

## CPC

- C12N 5/0696: {Artificially induced pluripotent stem cells, e.g. iPS}
- C12N 15/85: for animal cells
- C12N 2310/11: Antisense
- C12N 2330/51: Specially adapted vectors
- C12N 2500/92: Medium free of human- or animal-derived components
- C12N 2501/115: Basic fibroblast growth factor (bFGF, FGF-2)
- C12N 2501/15: Transforming growth factor beta (TGF-β)
- C12N 2501/602: Sox-2
- C12N 2501/603: Oct-3/4
- C12N 2501/604: Klf-4
- C12N 2501/727: Kinases (EC 2.7.)
- C12N 2506/03: from non-embryonic pluripotent stem cells
- C12N 2506/09: from epidermal cells, from skin cells, from oral mucosa cells
- C12N 2506/11: from blood or immune system cells
- C12N 2506/115: from monocytes, from macrophages
- C12N 2510/00: Genetically modified cells
- C12N 2710/00041: Use of virus, viral particle or viral elements as a vector
- C12N 2800/108: episomal vectors
- C12N 2800/24: Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication
- C12N 2820/60: from viruses
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Methods are disclosed for reprogramming a somatic cell, including an adherent cell and a cell in suspension, into an induced pluripotent stem comprising expressing exogenous Sox-2, exogenous Klf-4, exogenous Oct3/4 from DNA that has not integrated into the genome of the somatic cell, suppressing p53 activity within the somatic cell, and exposing the somatic cell to reprogramming-assistance factors comprising an exogenous Alk-5 inhibitor, an exogenous histone deacetylase inhibitor, and an exogenous activator of glycolysis. Compositions and kits for use in such methods are also disclosed as are cells made by such a method.

## Claims

### Claim 1

A method for reprogramming a somatic cell into an induced pluripotent stem (iPS) cell in vitro comprising:
expressing exogenous sex determining region Y-box 2 (Sox-2), Kruppel-like factor 4 (Klf-4), and octamer-binding transcription factor 3/4 (Oct3/4) in the somatic cell from DNA that has not integrated into genomic DNA of the somatic cell; and
culturing the somatic cell in a reprogramming medium comprising an exogenous activating receptor-like kinase 5 (Alk-5) inhibitor, an exogenous histone deacetylase inhibitor, an exogenous activator of glycolysis, and ascorbic acid to obtain an iPS cell.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the method further comprises expressing exogenous Epstein-Bar nuclear antigen-1 (EBNA-1) in the somatic cell from DNA that has not integrated into the genomic DNA of the somatic cell, and wherein the DNA that has not integrated into the genomic DNA of the somatic cell comprises at least one plasmid with an Epstein-Barr virus origin of replication (oriP).

### Claim 3 (depends on 2)

The method according to claim 2, which yields an integration-free, virus-free, exogenous oncogene-free iPS cell.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the iPS cell is a human iPS cell.

### Claim 5 (depends on 3)

The method according to claim 3, wherein the iPS cell is differentiated into an endodermal, mesodermal, or ectodermal cell.

### Claim 6 (depends on 1)

The method according to claim 1, wherein one or more of lung myelocytomatosis oncogene (L-Myc), c-myelocytomatosis oncogene (c-Myc), Lin28, simian virus 40 large T antigen, and Nanog are not exogenously expressed.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the reprogramming efficiency exceeds 0.0006%.

### Claim 8 (depends on 6)

The method according to claim 6, wherein the reprogramming efficiency exceeds 0.001%.

### Claim 9 (depends on 1)

The method according to claim 1, further comprising maintaining the cell in a dedifferentiation maintenance medium comprising basic fibroblast growth factor and transforming growth factor beta after being cultured in the reprogramming medium.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the culturing does not require feeder cells.

### Claim 11 (depends on 1)

The method according to claim 1, which further comprises inhibiting p53 activity in the somatic cell.

### Claim 12 (depends on 11)

The method according to claim 11, wherein inhibiting p53 activity in the somatic cell comprises suppressing p53 expression in the somatic cell, inhibiting p53-induced cell cycle arrest, and/or p53-induced apoptosis.

### Claim 13 (depends on 12)

The method according to claim 12, wherein suppressing p53 expression comprises expressing antisense p53 RNA in the somatic cell from DNA that has not integrated into the genomic DNA of the somatic cell.

### Claim 14 (depends on 1)

The method according to claim 1, wherein
the Alk-5 inhibitor comprises 3-(6-Methyl-2-pyridinyl)-N-phenyl-4-(4-quinolinyl)-1H-pyrazole-1-carbothioamide (A83-01);
the histone deacetylase inhibitor comprises sodium butyrate or valproic acid; and
the activator of glycolysis comprises a phosphoinositide-dependent protein kinase-1 inhibitor selected from 5-(4-Chloro-phenyl)-3-phenyl-pent-2-enoic acid (PS48); α,α,-Dimethyl-4-[2-methyl-8-[2-(3-pyridinyl)ethynyl]-1H-imidazo[4,5-c]quinolin-1-yl]-benzeneacetonitrile (BAG956); N-[3-[[5-Iodo-4-[[3-[(2-thienylcarbonyl)amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide (BX795); (3S,6R)-1-[6-(3-Amino-1H-indazol-6-yl)-2-(methylamino)-4-pyrimidinyl]-N-cyclohexyl-6-methyl-3-piperidinecarboxamide (GSK 2334470); 2-Amino-N-[4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]acetamide (OSU03012); and 4-Dodecyl-N-1,3,4-thiadiazol-2-yl-benzenesulfonamide (PHT427).

### Claim 15 (depends on 1)

The method according to claim 1, wherein the somatic cell is an isolated cord blood or peripheral blood mononuclear cell, and wherein the method further comprises pre-culturing the isolated cord blood or peripheral blood mononuclear cell in hematopoietic stem cell expansion media.

### Claim 16 (depends on 1)

The method according to claim 1, the somatic cell being free of exogenous oncogenes and retroviruses.

### Claim 17 (depends on 1)

The method according to claim 1, wherein colonies of iPS cells are obtained and 100% of the colonies express stage-specific embryonic antigen-4 (SSEA-4).

### Claim 18 (depends on 1)

The method according to claim 1, the somatic cell being an adherent cell.

### Claim 19 (depends on 1)

The method according to claim 1, wherein
the Alk-5 inhibitor comprises 3-(6-Methyl-2-pyridinyl)-N-phenyl-4-(4-quinolinyl)-1H-pyrazole-1-carbothioamide (A83-01);
the histone deacetylase inhibitor comprises sodium butyrate; and
the activator of glycolysis comprises 5-(4-Chloro-phenyl)-3-phenyl-pent-2-enoic acid (PS48).
